Cancer

Currently, about five in 10 women diagnosed with breast cancer in Africa survive for at least five years after diagnosis.

Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.

Over the past five years, the collaboration has supported more than 1,300 WellSpan patients across 12 cancer subspecialties through physician consultations, multidisciplinary tumour conferences and access to Johns Hopkins subspecialists.

The deal will give BioMarin access to ALE1, Alesta’s lead clinical-stage candidate for hypophosphatasia (HPP), a rare genetic bone disorder.

Tauklarify’s approval comes as the Alzheimer’s diagnostics field increasingly explores less invasive approaches, particularly blood-based tests for phosphorylated tau (pTau).

The U.S. National Cancer Institute estimates that more than 500 rare cancers exist, many of which receive limited public attention despite their significant impact on patients and families.

The researchers say the finding could help guide the development of more targeted treatment combinations for patients whose tumors produce the protein.

The approval allows the company’s PGDx elio tissue complete CDx to be used in hospitals and clinical laboratories across the United States to help identify patients who may benefit from targeted treatment.